Compass Pathways PLC Sponsored ADR (NASDAQ:CMPS - Get Free Report) saw unusually-strong trading volume on Friday . Approximately 3,335,025 shares traded hands during mid-day trading, a decline of 3% from the previous session's volume of 3,423,156 shares.The stock last traded at $9.1170 and had previously closed at $9.15.
Wall Street Analysts Forecast Growth
Several research analysts recently commented on CMPS shares. Lifesci Capital upgraded Compass Pathways to a "strong-buy" rating in a research report on Thursday, February 12th. B. Riley Financial started coverage on shares of Compass Pathways in a research note on Friday. They issued a "buy" rating and a $17.00 price objective for the company. Canaccord Genuity Group decreased their price objective on shares of Compass Pathways from $20.00 to $18.00 and set a "buy" rating for the company in a research note on Thursday, March 26th. Compass Point set a $15.00 price objective on shares of Compass Pathways in a research note on Thursday, February 12th. Finally, Morgan Stanley decreased their price objective on shares of Compass Pathways from $18.00 to $16.00 and set an "overweight" rating for the company in a research note on Wednesday, March 25th. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $20.70.
Read Our Latest Report on CMPS
Compass Pathways Stock Up 4.7%
The company's 50 day moving average price is $6.60 and its two-hundred day moving average price is $6.44. The company has a quick ratio of 0.77, a current ratio of 0.77 and a debt-to-equity ratio of 0.55. The stock has a market cap of $1.24 billion, a P/E ratio of -3.10 and a beta of 2.01.
Compass Pathways (NASDAQ:CMPS - Get Free Report) last posted its quarterly earnings results on Tuesday, March 24th. The company reported ($1.00) earnings per share for the quarter, missing the consensus estimate of ($0.41) by ($0.59). As a group, research analysts expect that Compass Pathways PLC Sponsored ADR will post -1.68 earnings per share for the current year.
Hedge Funds Weigh In On Compass Pathways
Several institutional investors have recently bought and sold shares of the business. North Star Investment Management Corp. increased its holdings in Compass Pathways by 1,354.0% during the first quarter. North Star Investment Management Corp. now owns 7,517 shares of the company's stock valued at $42,000 after buying an additional 7,000 shares during the period. Flax Pond Capital LLC purchased a new position in Compass Pathways during the fourth quarter valued at approximately $364,000. Caitong International Asset Management Co. Ltd purchased a new position in Compass Pathways during the fourth quarter valued at approximately $47,000. Seven Fleet Capital Management LP purchased a new position in Compass Pathways during the fourth quarter valued at approximately $276,000. Finally, Corient Private Wealth LLC increased its holdings in Compass Pathways by 3.2% during the fourth quarter. Corient Private Wealth LLC now owns 38,438 shares of the company's stock valued at $265,000 after buying an additional 1,200 shares during the period. 46.19% of the stock is owned by hedge funds and other institutional investors.
About Compass Pathways
(
Get Free Report)
Compass Pathways NASDAQ: CMPS is a clinical-stage biotechnology company focused on the development and commercialization of psilocybin therapy for mental health disorders. Founded in 2016 and headquartered in London with additional offices in the United States, Compass Pathways is pioneering the use of synthetic psilocybin combined with psychotherapy to address treatment-resistant depression. The company’s flagship program is a Phase IIb clinical trial evaluating COMP360, its proprietary psilocybin formulation, which has received Breakthrough Therapy designation from the U.S.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Compass Pathways, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Compass Pathways wasn't on the list.
While Compass Pathways currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead.
This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
